Clinical Trial Update: Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating a combination of Olaparib, Pembrolizumab, and Carboplatin as first-line therapy for recurrent or metastatic head and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• KEYTRUDA (PEMBROLIZUMAB)
• Olaparib (Olaparib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING